Mei-Kwan Yau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mei-Kwan Yau has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- David P. Fairlie
Centre for Chemistry and Drug Discovery Institute for Molecular Bioscience The University of Queensland Brisbane Queensland Australia
18 shared publications - Junxian Lim
Centre for Chemistry and Drug Discovery Institute for Molecular Bioscience The University of Queensland Brisbane Queensland Australia
15 shared publications - Jacky Y. Suen
The University of Queensland
12 shared publications - Robert C. Reid
Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia
11 shared publications - Ligong Liu
Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia
8 shared publications - Rink-Jan Lohman
Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Qld 4072, Australia
6 shared publications
Latest Publications
- 1 March 2021
- Published by Elsevier in Current Biology
- Vol. 31 (6) , 1326-1336.e5
Mechanotransduction activates RhoA in the neighbors of apoptotic epithelial cells to engage apical extrusion
- 1 March 2021
- Published by Elsevier in Current Biology
- Vol. 31 (6) , 1326-1336.e5
Mechanotransduction activates RhoA in the neighbors of apoptotic epithelial cells to engage apical extrusion
- 6 July 2020
- Published by Springer Nature in Nature Nanotechnology
- Vol. 15 (8) , 724
Publisher Correction: Programmable multistage drug delivery to lymph nodes
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
- 6 July 2020
- Published by Springer Nature in Nature Nanotechnology
- Vol. 15 (8) , 724
Publisher Correction: Programmable multistage drug delivery to lymph nodes
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
- Open Access
- 1 June 2020
- Published by Springer Nature in Nature Nanotechnology
- Vol. 15 (6) , 491-499
Programmable multistage drug delivery to lymph nodes
Therapeutic delivery selectively to lymph nodes has the potential to address a variety of unmet clinical needs. However, owing to the unique structure of the lymphatics and the size-restrictive nature of the lymph node reticular network, delivering cargo to specific cells in the lymph node cortex and paracortex is difficult. Here, we describe a delivery system to overcome lymphatic and intra-lymph node transport barriers by combining nanoparticles that are rapidly conveyed to draining lymph nodes after administration in peripheral tissues with programmable degradable linkers. This platform enables the controlled release of intra-lymph-mobile small-molecular cargo, which can reach vastly more immune cells throughout the lymph node than either the particles or free compounds alone. The release rate can be programmed, allowing access to different lymph node structures and therefore specific lymphocyte subpopulations. We are thus able to alter the subtypes of drugged lymph node cells to improve immunotherapeutic effects.
- 1 June 2020
- Published by Springer Nature in Nature Nanotechnology
- Vol. 15 (6) , 491-499
Open AccessProgrammable multistage drug delivery to lymph nodes
Therapeutic delivery selectively to lymph nodes has the potential to address a variety of unmet clinical needs. However, owing to the unique structure of the lymphatics and the size-restrictive nature of the lymph node reticular network, delivering cargo to specific cells in the lymph node cortex and paracortex is difficult. Here, we describe a delivery system to overcome lymphatic and intra-lymph node transport barriers by combining nanoparticles that are rapidly conveyed to draining lymph nodes after administration in peripheral tissues with programmable degradable linkers. This platform enables the controlled release of intra-lymph-mobile small-molecular cargo, which can reach vastly more immune cells throughout the lymph node than either the particles or free compounds alone. The release rate can be programmed, allowing access to different lymph node structures and therefore specific lymphocyte subpopulations. We are thus able to alter the subtypes of drugged lymph node cells to improve immunotherapeutic effects.
- 7 January 2020
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (2) , 529-541
Potent Thiophene Antagonists of Human Complement C3a Receptor with Anti-Inflammatory Activity
Structure–activity relationships for a series of small-molecule thiophenes resulted in potent and selective antagonism of human Complement C3a receptor. The compounds are about 100-fold more potent than the most reported antagonist SB290157. A new compound JR14a was among the most potent of the new antagonists in vitro, assessed by (a) inhibition of intracellular calcium release (IC50 10 nM) induced in human monocyte-derived macrophages by 100 nM C3a, (b) inhibition of β-hexosaminidase secretion (IC50 8 nM) from human LAD2 mast cells degranulated by 100 nM C3a, and (c) selectivity for human C3aR over C5aR. JR14a was metabolically stable in rat plasma and in rat liver microsomes and efficacious in rats when given orally to suppress rat paw inflammation, macrophage and mast cell activation, and histopathology induced by intraplantar paw administration of a C3aR agonist. Potent C3aR antagonists are now available for interrogating C3a receptor activation and suppressing C3aR-mediated inflammation in mammalian physiology and disease.
- 7 January 2020
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (2) , 529-541
Potent Thiophene Antagonists of Human Complement C3a Receptor with Anti-Inflammatory Activity
Structure–activity relationships for a series of small-molecule thiophenes resulted in potent and selective antagonism of human Complement C3a receptor. The compounds are about 100-fold more potent than the most reported antagonist SB290157. A new compound JR14a was among the most potent of the new antagonists in vitro, assessed by (a) inhibition of intracellular calcium release (IC50 10 nM) induced in human monocyte-derived macrophages by 100 nM C3a, (b) inhibition of β-hexosaminidase secretion (IC50 8 nM) from human LAD2 mast cells degranulated by 100 nM C3a, and (c) selectivity for human C3aR over C5aR. JR14a was metabolically stable in rat plasma and in rat liver microsomes and efficacious in rats when given orally to suppress rat paw inflammation, macrophage and mast cell activation, and histopathology induced by intraplantar paw administration of a C3aR agonist. Potent C3aR antagonists are now available for interrogating C3a receptor activation and suppressing C3aR-mediated inflammation in mammalian physiology and disease.
- 1 March 2017
- Published by Elsevier in Pharmacological Research
- Vol. 117, 328-342
Mapping transmembrane residues of proteinase activated receptor 2 (PAR2) that influence ligand-modulated calcium signaling
- 1 March 2017
- Published by Elsevier in Pharmacological Research
- Vol. 117, 328-342
Mapping transmembrane residues of proteinase activated receptor 2 (PAR2) that influence ligand-modulated calcium signaling
- 21 October 2016
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 7 (12) , 1179-1184
PAR2 Modulators Derived from GB88
PAR2 antagonists have potential for treating inflammatory, respiratory, gastrointestinal, neurological, and metabolic disorders, but few antagonists are known. Derivatives of GB88 (3) suggest that all four of its components bind at distinct PAR2 sites with the isoxazole, cyclohexylalanine, and isoleucine determining affinity and selectivity, while the C-terminal substituent determines agonist/antagonist function. Here we report structurally similar PAR2 ligands with opposing functions (agonist vs antagonist) upon binding to PAR2. A biased ligand AY117 (65) was found to antagonize calcium release induced by PAR2 agonists trypsin and hexapeptide 2f-LIGRLO-NH2 (IC50 2.2 and 0.7 μM, HT29 cells), but it was a selective PAR2 agonist in inhibiting cAMP stimulation and activating ERK1/2 phosphorylation. It showed anti-inflammatory properties both in vitro and in vivo.
- 21 October 2016
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 7 (12) , 1179-1184
PAR2 Modulators Derived from GB88
PAR2 antagonists have potential for treating inflammatory, respiratory, gastrointestinal, neurological, and metabolic disorders, but few antagonists are known. Derivatives of GB88 (3) suggest that all four of its components bind at distinct PAR2 sites with the isoxazole, cyclohexylalanine, and isoleucine determining affinity and selectivity, while the C-terminal substituent determines agonist/antagonist function. Here we report structurally similar PAR2 ligands with opposing functions (agonist vs antagonist) upon binding to PAR2. A biased ligand AY117 (65) was found to antagonize calcium release induced by PAR2 agonists trypsin and hexapeptide 2f-LIGRLO-NH2 (IC50 2.2 and 0.7 μM, HT29 cells), but it was a selective PAR2 agonist in inhibiting cAMP stimulation and activating ERK1/2 phosphorylation. It showed anti-inflammatory properties both in vitro and in vivo.
- Open Access
- 20 April 2016
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 1-12
Receptor residence time trumps drug-likeness and oral bioavailability in determining efficacy of complement C5a antagonists
Drug discovery and translation are normally based on optimizing efficacy by increasing receptor affinity, functional potency, drug-likeness (rule-of-five compliance) and oral bioavailability. Here we demonstrate that residence time of a compound on its receptor has an overriding influence on efficacy, exemplified for antagonists of inflammatory protein complement C5a that activates immune cells and promotes disease. Three equipotent antagonists (3D53, W54011, JJ47) of inflammatory responses to C5a (3nM) were compared for drug-likeness, receptor affinity and antagonist potency in human macrophages, and anti-inflammatory efficacy in rats. Only the least drug-like antagonist (3D53) maintained potency in cells against higher C5a concentrations and had a much longer duration of action (t1/2 ~ 20 h) than W54011 or JJ47 (t1/2 ~ 1–3 h) in inhibiting macrophage responses. The unusually long residence time of 3D53 on its receptor was mechanistically probed by molecular dynamics simulations, which revealed long-lasting interactions that trap the antagonist within the receptor. Despite negligible oral bioavailability, 3D53 was much more orally efficacious than W54011 or JJ47 in preventing repeated agonist insults to induce rat paw oedema over 24 h. Thus, residence time on a receptor can trump drug-likeness in determining efficacy, even oral efficacy, of pharmacological agents.
- 20 April 2016
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 1-12
Open AccessReceptor residence time trumps drug-likeness and oral bioavailability in determining efficacy of complement C5a antagonists
Drug discovery and translation are normally based on optimizing efficacy by increasing receptor affinity, functional potency, drug-likeness (rule-of-five compliance) and oral bioavailability. Here we demonstrate that residence time of a compound on its receptor has an overriding influence on efficacy, exemplified for antagonists of inflammatory protein complement C5a that activates immune cells and promotes disease. Three equipotent antagonists (3D53, W54011, JJ47) of inflammatory responses to C5a (3nM) were compared for drug-likeness, receptor affinity and antagonist potency in human macrophages, and anti-inflammatory efficacy in rats. Only the least drug-like antagonist (3D53) maintained potency in cells against higher C5a concentrations and had a much longer duration of action (t1/2 ~ 20 h) than W54011 or JJ47 (t1/2 ~ 1–3 h) in inhibiting macrophage responses. The unusually long residence time of 3D53 on its receptor was mechanistically probed by molecular dynamics simulations, which revealed long-lasting interactions that trap the antagonist within the receptor. Despite negligible oral bioavailability, 3D53 was much more orally efficacious than W54011 or JJ47 in preventing repeated agonist insults to induce rat paw oedema over 24 h. Thus, residence time on a receptor can trump drug-likeness in determining efficacy, even oral efficacy, of pharmacological agents.
- 3 March 2016
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 26 (4) , 471-483
Protease activated receptor 2 (PAR2) modulators: a patent review (2010–2015)
Introduction: Protease activated receptor 2 (PAR2) is a self-activated G protein-coupled receptor that has been implicated in several diseases, including inflammatory, gastrointestinal, respiratory...
- 3 March 2016
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 26 (4) , 471-483
Protease activated receptor 2 (PAR2) modulators: a patent review (2010–2015)
Introduction: Protease activated receptor 2 (PAR2) is a self-activated G protein-coupled receptor that has been implicated in several diseases, including inflammatory, gastrointestinal, respiratory...
- 1 February 2016
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 26 (3) , 986-991
Benzylamide antagonists of protease activated receptor 2 with anti-inflammatory activity
- 1 February 2016
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 26 (3) , 986-991
Benzylamide antagonists of protease activated receptor 2 with anti-inflammatory activity
- 3 December 2015
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 7 (1) , 105-110
Potent Small Agonists of Protease Activated Receptor 2
Many proteases cut the PAR2 N-terminus resulting in conformational changes that activate cells. Synthetic peptides corresponding to newly exposed N-terminal sequences of PAR2 also activate the receptor at micromolar concentrations. PAR2-selective small molecules reported here induce PAR2-mediated intracellular calcium signaling at nanomolar concentrations (EC50 = 15–100 nM, iCa2+, CHO-hPAR2 cells). These are the most potent and efficient small molecule ligands to activate PAR2-mediated calcium release and chemotaxis, including for human breast and prostate cancer cells.
- 3 December 2015
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 7 (1) , 105-110
Potent Small Agonists of Protease Activated Receptor 2
Many proteases cut the PAR2 N-terminus resulting in conformational changes that activate cells. Synthetic peptides corresponding to newly exposed N-terminal sequences of PAR2 also activate the receptor at micromolar concentrations. PAR2-selective small molecules reported here induce PAR2-mediated intracellular calcium signaling at nanomolar concentrations (EC50 = 15–100 nM, iCa2+, CHO-hPAR2 cells). These are the most potent and efficient small molecule ligands to activate PAR2-mediated calcium release and chemotaxis, including for human breast and prostate cancer cells.